Davide Capodanno/X
Jul 8, 2025, 07:56
AUREA – No Added Benefit of Short-Term OAC Post-TAVI in Patients Without OAC Indication
Davide Capodanno, Professor of Cardiology at University of Catania, Italy has posted on X:
“In the randomized, open-label AUREA trial, an OAC strategy for 3 months post-TAVI did not show any benefit over an antiplatelet strategy in preventing cerebral microembolism in patients without an indication for OAC. Patients treated with DAPT showed a lower mean volume of brain damage on DW-MRI during the 90 days following TAVI compared to those treated with acenocoumarol.”
You can read the Full Article here.
Explore more on Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis